(redirected from Cytopenias)
Also found in: Dictionary, Medical, Encyclopedia.
  • noun

Words related to cytopenia

a deficiency of some cellular element of the blood

References in periodicals archive ?
All patients exhibited cytopenias during their stay, although cell counts often fluctuated markedly, most commonly following transfusion of blood products.
5 2) Splenomegaly 3) Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood) 4) Hypertriglyceridemia (>265 mg/dL, fasting) and/or hypofibrinogenemia (<150 mg/dL) 5) Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver 6) Low or absent NK-cell activity 7) Ferritin >500 ng/mL 8) Elevated soluble CD25 (alpha chain of soluble IL-2 receptor)
RAEB-1 is defined by cytopenias with unilineage or multilineage dysplasia and 5% to 9% blasts in bone marrow or 2% to 4% blasts in the peripheral blood.
As the etiologies of peripheral blood cytopenias are broad, and the findings are often nonspecific, bone marrow biopsies are often performed in cytopenic patients, especially to exclude both hematologic and nonhematologic malignancies.
Shortly thereafter some cases of refractory cytopenia were noted to develop into leukaemia, giving rise to the term pre-leukaemia.
5[degrees]C; hypertriglyceridemia at 267 mg/dL (analysis performed at day 7); and cytopenias, which preferentially affected erythrocytes and lymphocytes.
Hematological manifestations are usually asymptomatic; however, serious cytopenias can develop in some cases, necessitating treatment.
In conclusion, rituximab therapy shows promise as an alternative to intensive immunosuppressive therapy and splenectomy in children with autoimmune cytopenias that are resistant to first-line therapy and cyclosporin/MMF.
They end with specific approaches to evaluating bone marrow that is primarily or secondarily involved by lymphoma and cytopenias due to non-neoplastic causes.
Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.
The methods and compositions are useful in stimulating hematopoiesis and in treating a wide range of conditions including cytopenias, anemias and for use in preparing cells for transplantation.
And many of these patients may not be referred for evaluation of their cytopenias.
Prolonged and Severe Cytopenias: Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients.